Too Old to Operate18h
Cerebral Ischemia Risk With Transfusion Strategies in SAH
The following is a summary of “Liberal versus restrictive transfusion strategies in subarachnoid hemorrhage: a secondary ...
Grace Therapeutics Announces Private Placement Financing of up to $30 Million
Financing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors$15 ...
Grace Therapeutics reports positive Phase 3 trial results for GTx-104
Grace Therapeutics Inc. (NASDAQ:GRCE), a $32.85 million market cap biotechnology company whose stock has gained over 37% in the past six months, has announced successful outcomes from its Phase 3 ...
Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study
Grace Therapeutics' GTx-104 met its Phase 3 trial endpoint, showing clinical benefits over oral nimodipine. US NDA submission ...
Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered NimodipineNew Drug Application ...
Grace Therapeutics secures up to $30 million financing
PRINCETON, N.J. - Grace Therapeutics, Inc. (NASDAQ:GRCE), a biopharmaceutical company focused on developing treatments for ...